Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Ris... (n tried first. Treatment with combina...)

HOME >> MEDICINE >> TECHNOLOGY

Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients

Date:3/31/2008

n tried first.

Treatment with combination therapy resulted in exceptional blood pressure control at 30 months. Before entering the study, almost all patients were treated with multiple high blood pressure medicines. At study entry, only 37% of the study population had a blood pressure of <140/90 mmHg, regarded in treatment guidelines as the appropriate goal for most patients. After switching to a single-pill combination of the study medications, 82% of patients taking Lotrel and 79% of patients taking the benazepril and HCTZ combination achieved blood pressure goal after 30 months. Some patients received additional medication to treat their high blood pressure.

"Evidence from trials like ACCOMPLISH provides physicians with additional information to better inform their treatment decisions in high-risk hypertensive patients," said Marjorie Gatlin, MD, Vice President and Head of Cardiovascular and Metabolism Medical Franchise US Medical and Drug Regulatory Affairs at Novartis Pharmaceuticals Corporation. "Novartis is an innovator of unique medications for the treatment of high blood pressure, including single- pill combinations, and is committed to further develop this approach for effective patient care."

The results were presented today in a late-breaking session at the American College of Cardiology 57th Annual Scientific Session in Chicago.

ACCOMPLISH is the first large clinical outcomes trial to directly compare two single-pill combinations of commonly used high blood pressure medicines in the reduction of a composite endpoint including heart attacks, strokes, hospitalizations for unstable angina and cardiovascular deaths in high blood pressure patients at high cardiovascular risk. In October 2007, the study was stopped early because the pre-defined efficacy outcome had been achieved.

The study was a multi-national, double-blind trial and included more than 11,000 patients at 550 study sites in the US and Scandinavia. One day aft
'/>"/>

8

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
2. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
3. New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
4. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
5. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
6. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. New Drug Combination is Able to Eradicate Breast Metastases in Mice
9. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Post Your Comments:

Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Ris...(n tried first. Treatment with combina...),Health